An observational study in Metastatic Breast Cancer, sponsored by Hellenic Cooperative Oncology Group. Completed at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Hellenic Cooperative Oncology Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group — 3 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Hellenic Cooperative Oncology Group.
Among the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, this one is the 13th largest by planned enrollment of the 14 observational ones that give a count, is the only one that started in 1998, is one of 14 observational ones, and was the 11th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →3 of the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group are open now, in 1 country. Recruiting first, the newest first:
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+ · Women only
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 1 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 101 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 82 across the 3 interventional studies, 423 across the 14 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hellenic Cooperative Oncology Group is the lead sponsor of 62 studies on the registry; 6 are open to participants now.
2 of the studies in Breast Neoplasms by Hellenic Cooperative Oncology Group that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04985058Hellenic Cooperative Oncology GroupReal-world Data in Patients With Breast Cancer Treated With Abemaciclib | 2026-11-30 |
| NCT07899463Hellenic Cooperative Oncology GroupESR1 Mutations in Metastatic Hormone Receptor-Positive Breast Cancer in the Greek Population | 2027-05-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine somatic and germline pathogenic variants in patients with denovo metastatic breast cancer in order to map the molecular/genetic characteristics of DN- MBC aiming in comprehending the biology and highlighting potential novel treatment options for the disease.
The value of this study is based on the fact that DN-MBC is rare, seems to be different from early and relapsed breast cancer and has not been studied as distinct disease. To achieve the objective of this study blood and tissue sample from patients diagnosed with DN-MBC will be further analyzed using next generation sequencing (NGS), in order to map the molecular/genetic characteristics of DN-MBC and to detect germline and somatic pathogenic variants. All the results will be associated with the clinicopathological characteristics of the patients.
patients will be selected from community or academic or private hospitals
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Inadequate MBC tissue
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood and tissue sample from patients diagnosed with DN-MBC will be analyzed using next generation sequencing (NGS)
Diagnostic Test: NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue
In patients with denovo metastatic breast cancer blood and tissue sample will be collected and then further analysed using NGS in order to detect somatic and germline pathogenic variants
Number of participants with somatic pathogenic variants in denovo metastatic breast cancer
Time frame: up to 12 months
Number of participants with germline pathogenic variants in denovo metastatic breast cancer
Time frame: up to 12 months
Definition of the somatic pathogenic variants measured with Next Generation Sequencing
Time frame: up to 12 months
Collection of clinicopathological characteristics of the included patients from patient's medical file
Time frame: up to 12 months
Definition of the germline pathogenic variants measured with Next Generation Sequencing
Time frame: up to 12 months
Ran from Jul 1998 to primary completion in Oct 2025, 327 months.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 327 months is above that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Oct 2010 → Oct 2025 and completion Jun 2023 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hellenic Cooperative Oncology Group